-- 受美伊可能達成協議的提振,中國股市連續第二天上漲。 上證綜指上漲0.5%,或19.92點,收在4180.09點。深證成指上漲1.2%,或182.27點,收在15641.89點。 美國總統川普表示,在美國提出結束戰爭的方案後,美伊進行了「非常好的會談」。 企業方面,遠東智慧能源(SHA:600869)股價上漲7.3%,此前該公司宣布4月獲得價值26.3億元人民幣的合約訂單。 內蒙古興業銀錫礦業(SHE:000426)股價上漲6.6%,此前該公司旗下子公司同意以1.64億元人民幣全資收購西藏陽光礦業投資有限公司。 晶科能源(SHA:601778)股價上漲3.8%,此前該公司決定不贖回價值30億元人民幣的提前到期債券,儘管該債券的贖回條款已被觸發。
Related Articles
Jagsonpal Pharmaceuticals Sets Dates for INR400 Million Buyback
Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM, BOM:507789) has fixed May 8 as the opening date and May 14 as the closing date for its share buyback plan worth 400 million, according to a Wednesday filing on Indian bourses.Shares of the company rose nearly 2% in Thursday's trade.The company will buy back up to 1.6 million equity shares at 250 rupees per share through the tender offer route, the filing said.
Research Alert: CFRA Maintains Strong Buy Opinion On Shares Of Arch Capital Group Ltd.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month targe price to $115 from ($118), valuing ACGL shares at 10.9x our '27 operating EPS estimate of $10.55 (lowered today by $0.40) and at 11.6x our '26 EPS estimate of $9.93 (cut by $0.12), versus the shares' three-year average forward multiple and the peer average of 12x. ACGL posted Q1 operating EPS of $2.50 vs. $1.54 the prior year, beating the $2.46 consensus but missing our $2.62 estimate. However, operating revenues declined 1.3% Y/Y, significantly below our 8%-15% growth forecast, reflecting 4.8% lower earned premiums partly offset by 8% higher investment income. We view ACGL as a top-tier underwriter with superior underwriting capabilities, maintaining strong profitability metrics despite competitive headwinds. We now see revenue growth of 3%-5% in 2026 and 2027. Underlying underwriting results remained superior to industry averages, with the combined ratio at 82.3% vs. 81.0% the prior year, about 5-10 points better than industry, which will support EPS.